Digestive Diseases Research Institute (DDRI), Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Gastrointestinal and Liver Diseases Research Center (GLDRC), Firoozgar Hospital, Iran University of Medical Sciences, Tehran, Iran.
Arch Iran Med. 2014 Jul;17(7):477-82.
So far, a variety of prevalence rates have been reported for the metabolic syndrome (MetS) according to several definitions. The aim of this study was to assess the prevalence of MetS in Iran according to two definitions and compare the characteristics of the subjects who met the MetS criteria according to the different definitions.
Participants were recruited from family registries of public health centers. After obtaining demographic and clinical data, the subjects underwent anthropometric measurements and laboratory evaluations. MetS was defined according to the NCEP-ATPIII and IDF criteria. The subjects were then categorized into 3 groups: 1) Healthy non-MetS subjects based on either definition, 2) Individuals with MetS according to only one of the definitions, and 3) Individuals who met both NCEP-ATPIII and IDF criteria for MetS.
Totally, 5826 subjects in Amol and 2243 subjects in Zahedan were enrolled in the study. The weighted prevalence of MetS according to the NCEP-ATPIII and IDF criteria was 27.8% and 26.9% in Amol and 12% and 11.8% in Zahedan, respectively. Overall, 18.9% of the subjects fulfilled both criteria for MetS. However, a considerable proportion (8.5%) met the MetS criteria according to only one definition but not both.
MetS is increasingly prevalent in Iran as well as other parts of the world. Due to non-uniform definitions of MetS, some of the subjects who meet MetS according to one set of criteria might be considered healthy according to another definition and consequently would not receive the preventive health services.
根据多种定义，目前已有多种代谢综合征（MetS）的流行率报道。本研究旨在评估伊朗按照两种定义的 MetS 流行率，并比较根据不同定义符合 MetS 标准的受试者的特征。
参与者从公共卫生中心的家庭登记处招募。在获得人口统计学和临床数据后，受试者接受了人体测量和实验室评估。MetS 根据 NCEP-ATPIII 和 IDF 标准定义。然后将受试者分为 3 组：1）根据任一标准均为健康非 MetS 受试者，2）根据仅一个标准患有 MetS 的个体，3）同时符合 NCEP-ATPIII 和 IDF 标准的 MetS 个体。
总计，阿摩尔有 5826 名受试者，扎黑丹有 2243 名受试者纳入研究。根据 NCEP-ATPIII 和 IDF 标准，阿摩尔 MetS 的加权流行率分别为 27.8%和 26.9%，扎黑丹分别为 12%和 11.8%。总体而言，18.9%的受试者符合 MetS 的两项标准。然而，相当一部分（8.5%）符合一项标准但不符合另一项标准的 MetS 标准。
MetS 在伊朗以及世界其他地区的流行率越来越高。由于 MetS 的定义不统一，根据一组标准符合 MetS 的一些受试者可能根据另一组定义被认为是健康的，因此不会获得预防保健服务。
